The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Abstract
Background Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease. Methods We did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries worldwide. We enrolled HIV-negative and human herpesvirus-8-seronegative patients with symptomatic multicentric Castleman's disease. Treatment allocation was randomised with a computer-generated list, with block size six, and stratification by baseline corticosteroid use. Patients and investigators were masked to treatment allocation. Patients were randomly assigned (2:1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo; all patients also received best supportive care. Patients continued treatment until treatment failure. The primary endpoint was durable tumour and symptomatic response for at least 18 weeks for the intention-to-treat population. Enrolment has been completed. The study is registered with ClinicalTrials.gov, number NCT01024036. Findings We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the pla…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A number of neutralizing antibodies directed against key components of the SASP or their receptors, including IL-6, IL-1α, IL-1β and TNF, also have shown senomorphic properties104,240–248 (TABLE 1).”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [248]
In the citing paper
“Siltuximab proved to be effective for the treatment of Castleman’s disease in worldwide clinical trials (van Rhee et al., 2014”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as van Rhee et al., 2014
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Localized mediastinal lymph-node hyperplasia resembling thymoma
Castleman, B., Iverson, L., & Menendez, V. P. (1956) · Cancer · doi:10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4 · Cited by 1,621
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
Self-citationMulticentric Giant Lymph Node Hyperplasia
Gaba, A. R., Stein, R. S., Sweet, D. L., & Variakojis, D. (1978) · American Journal of Clinical Pathology · doi:10.1093/ajcp/69.1.86 · Cited by 359
Surgery in Castleman's Disease: A Systematic Review of 404 Published Cases
Talat, N., Belgaumkar, A. P., & Schulte, K.-M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318249dcdc · Cited by 355
Casper, C. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05311.x · Cited by 354
Self-citationFajgenbaum, D. C., van Rhee, F., & Nabel, C. S. (2014) · Blood · doi:10.1182/blood-2013-12-545087 · Cited by 331
Self-citationCastleman Disease: An Update on Classification and the Spectrum of Associated Lesions
Cronin, D. M. P., & Warnke, R. A. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4d3 · Cited by 311
The clinical spectrum of Castleman's disease
Dispenzieri, A., Armitage, J. O., Loe, M. J., Geyer, S. M., Allred, J., Camoriano, J. K., Menke, D. M., Weisenburger, D. D., Ristow, K., Dogan, A., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23291 · Cited by 244
Research works printed but not linked: 1
- Castleman, 1954, Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C Cabot, N Engl J Med, 251, 396
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Metadata
- Authors
- van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., Goh, Y. T., Zhu, J., Cho, S.-G., Ren, H., Cavet, J., Bandekar, R., Rothman, M., Puchalski, T. A., Reddy, M., van de Velde, H., Vermeulen, J., & Casper, C.
- Affiliations
- Chinese University of Hong Kong (HK)
- Dana-Farber Cancer Institute (US)
- Oslo University Hospital (NO)
- North Shore Hospital (NZ)
- Hospital Mãe de Deus (BR)
- Sichuan University (CN)
- Mackay Memorial Hospital (TW)
- Singapore General Hospital (SG)
- Peking University Cancer Hospital (CN)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Peking University First Hospital (CN)
- University of Manchester (GB)
- Janssen Research & Development (United States) (US)
- Janssen (Netherlands) (NL)
- Fred Hutch Cancer Center (US)
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 15
- Issue
- 9
- Pages
- 966-974
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2169031812
- Cited by
- 454
- References
- 24
- Citations by year
- 2026: 37 · 2025: 32 · 2024: 36 · 2023: 33 · 2022: 56 · 2021: 39 · 2020: 45 · 2019: 21 · 2018: 41 · 2017: 40 · 2016: 29 · 2015: 38 · 2014: 5
- FWCI
- 18.00
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-09-01)
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multicentric Castleman disease, siltuximab, interleukin-6, chimeric monoclonal antibody, lymphoproliferative disorders, tumor response, adverse events, HIV-negative patients, human herpesvirus 8, corticosteroid use, fatigue, anemia, night sweats, treatment duration, best supportive care, comparative efficacy and safety
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Castleman Disease, Humans, Infusions, Intravenous, International Cooperation, Male, Middle Aged, Reference Values, Severity of Illness Index, Survival Rate, Confidence Intervals, Treatment Outcome, Risk Assessment, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(14)70319-5
- The paper
- van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., Goh, Y. T., Zhu, J., Cho, S.-G., Ren, H., Cavet, J., Bandekar, R., Rothman, M., Puchalski, T. A., Reddy, M., . . . Casper, C. (2014). Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)70319-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.